About verrica pharmaceuticals inc - VRCA
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
VRCA At a Glance
Verrica Pharmaceuticals, Inc.
44 West Gay Street
West Chester, Pennsylvania 19380
| Phone | 1-434-453-3300 | Revenue | 7.57M | |
| Industry | Pharmaceuticals: Major | Net Income | -76,579,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 47.658% | |
| Fiscal Year-end | 12 / 2025 | Employees | 71 | |
| View SEC Filings |
VRCA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.793 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.564 |
| Enterprise Value to Sales | 4.742 |
| Total Debt to Enterprise Value | 1.281 |
VRCA Efficiency
| Revenue/Employee | 106,563.38 |
| Income Per Employee | -1,078,577.465 |
| Receivables Turnover | 98.26 |
| Total Asset Turnover | 0.111 |
VRCA Liquidity
| Current Ratio | 1.764 |
| Quick Ratio | 1.679 |
| Cash Ratio | 1.597 |
VRCA Profitability
| Gross Margin | 63.785 |
| Operating Margin | -857.534 |
| Pretax Margin | -1,012.146 |
| Net Margin | -1,012.146 |
| Return on Assets | -112.439 |
| Return on Equity | -1,546.582 |
| Return on Total Capital | -212.254 |
| Return on Invested Capital | -175.949 |
VRCA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 127.329 |
| Total Debt to Total Assets | 84.111 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 89.62 |